Piper Sandler analyst Biren Amin maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target ...

William Blair analyst Sami Corwin has reiterated their bullish stance on ALLO stock, giving a Buy rating on November 11. Sami Corwin has given ...

David Axe is a journalist and filmmaker based in Columbia, South Carolina. He joined Forbes in 2020, and currently focuses on Ukraine.

Allogene Therapeutics has dropped plans to target one of its allogeneic CAR-Ts at leukemia in the face of competition from the likes of Bristol Myers Squibb. The biotech had been enrolling ...

After hours: November 15 at 7:41 PM EST Loading Chart for ALLO ...

Li Chang was born in China in 1929, and grew up in a family that cherished traditional Chinese art. From a young age, he showed a natural talent for painting and a deep appreciation for the beauty in ...

A longtime conservative, alienated by Trumpism, tries to come to terms with life on the moderate edge of the Democratic Party.

Allogene Therapeutics, Inc. (NASDAQ:ALLO) has announced the cessation of patient enrollment in a Phase 1 clinical trial cohort for cemacabtagene ansegedleucel (cema-cel) as of Monday. The trial ...

SEC Filings provided by EDGAR Online, Inc.

Allogene is ceasing enrollment in a Phase I trial of cema-cel for patients with relapsed or refractory chronic lymphocytic leukemia after Bristol Myers Squibb’s Breyanzi was approved in the indication ...